A $9 million grant from ASAP and The Michael J. Fox Foundation funds an Indiana University-led study on immune cell exhaustion in Parkinson's disease, aiming to develop personalized immunotherapies. The multi-institutional team will map immune system changes to uncover biomarkers and explain disease heterogeneity. Advances in proteomics are also enabling molecular subtyping and precision medicine across neurological disorders.
New research demonstrates that blood tests measuring p-tau217 protein can identify dementia risk up to 25 years before symptoms and significantly improve diagnostic accuracy in clinical practice.
Researchers at Washington University School of Medicine developed a blood test-based method to predict when Alzheimer's symptoms will begin, with accuracy within three to four years, using plasma p-tau217 protein levels.
A single blood test measuring p-tau217 protein can predict when cognitively unimpaired individuals will develop Alzheimer's symptoms, with a margin of error of 3-4 years, potentially accelerating clinical trials.
